tbuckley/cabot-search huggingface dataset:
Expression and the prognostic relevance of p53, Bcl-2, Bax, and Ki-67 in uterine leiomyosarcoma.
Authors: Irina Rezo Gagua
Journal: Journal of Clinical Oncology (2012)

e15506 Background: Uterine leiomyosarcomas (LMS) are rare, aggressive gynecological malignancies of the female reproductive tract. They represent less than 2-5% of all uterine malignancies. Despite the advanced modern treatment modalities, according to our data 5 year overall and disease - free survival of patients with LMS is 48,5± 4,2% and 44.3 ± 4.3 %, respectively. One of the challenging directions in advancing the prognosis and optimization of treatment tactics in LMS is investigating the expression of molecular-biological markers in tumor tissue. So, the aim of our study was to evaluate the expression of p53, Bcl-2, Bax, and Ki-67 and their prognostic relevance. Methods: A retrospective chart review was done to 198 patients with LMS treated at the N.N. Blokhin Russian Cancer Research Center from 1971 to 2009. Immunohistochemical (IHC) staining for 20 patients was performed for p53, Bcl-2, Bax and Ki-67. Negative and positive IHC staining was scored for each marker. Survival was determined from the time of initial diagnosis to last follow-up. Results: Ten (50%) patients with LMS expressed p53. P53 + patients mostly had multiple metastases, compared to p53 – patients with solitar metastases (60% against 20%) (g&lt;0,05). Eleven (55%) patients expressed Bcl-2 and 4 (20%) expressed Bax. In Bcl-2 + patients distant metastases were observed in 45,5%, compared to Bcl-2 – patients were we observed metastatic disease in 77,8% (p=0,068). Expression of ki-67 was observed in 15 patients (75%). Conclusions: LMS patients with p53 expression had a poorer survival compared to LMS patients with negative expression (g53 + — 26,7±18,4% and g53 – — 80,0±12,6%) (g&lt;0,05). On opposite, the disease-free survivla is better in bcl-2 + patients, compared to patients, who don’t express bcl-2 (47,2±19,6% and 28,1±18,0%, respectevly (g&gt;0,05). We didn’t observe statistical significant difference in survival depending on Bax expression. LMS patients with Ki-67 expression had a poorer survival compared to LMS patients with negative expression (34,9±13,1% and 60,0±20,7% , respectively) (g&gt;0,05). Our study indicates that p53 expression may serve as a prognostic marker for LMS patients.
HEMODYNAMIC EFFECTS OF NITROXYL DONOR BMS-986231 COMPARED TO NITROGLYCERIN OR PLACEBO IN PATIENTS WITH CHRONIC HEART FAILURE-A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL
Authors: G. Michael Felker, John McMurray, John Cleland, Christopher O'Connor, John Teerlink, Adriaan Voors, Ninian Lang, Faheem Ahmad, Jorg Taubel, Anke Koehorst-Hodes, David E. Newby, Ravi Karra, Yasushi Sakata, Shiro Ishihara, Roxy Senior, Abhishek Khemka, Scott D. Solomon, Mimi Desouza, Dietmar Seiffert, June Ye, Paul Kessler, Maria Borentain
Journal: Journal of the American College of Cardiology (2020)
DIFFERENCES IN THERAPY AND DECONGESTION BETWEEN MEN AND WOMEN HOSPITALIZED FOR ACUTE HEART FAILURE: FINDINGS FROM ASCEND-HF
Authors: Vanessa Blumer, Stephen Greene, Angie Wu, JoAnn Lindenfeld, Brooke Alhanti, Javed Butler, Justin Ezekowitz, Adrian Hernandez, Mariell Jessup, Robert John Mentz
Journal: Journal of the American College of Cardiology (2020)
Protecting Patients and Our Profession
Authors: Rachel R. Kelz, William O. Cooper
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
THE IMPACT OF SONOTHROMBOLYSIS ON LEFT VENTRICULAR DIASTOLIC FUNCTION AND LEFT ATRIAL MECHANICS IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION
Authors: Hsu Chiang, Miguel Osman Aguiar, Bruno Garcia Tavares, Wilson Mathias, Bruno Carter Borges, Luciene Azevedo, Mucio Oliveira, Alexandre Soeiro, Jose C. Nicolau, Henrique B. Ribeiro, João Cesar Sbano, Andrew Goldsweig, Roberto Kalil-Filho, Jose Ramires, Thomas Porter, Jeane Tsutsui
Journal: Journal of the American College of Cardiology (2020)
Phase III randomized controlled trial of hypotonic intraperitoneal cisplatin combined with oral UFT/PSK for the adjuvant treatment of gastric cancer invading the serosa
Authors: S. Tsujitani, H. Saito, S. Tatebe, M. Ikeguchi
Journal: Journal of Clinical Oncology (2006)

4027 Background: Peritoneal seeding is the most common pattern of recurrence in patients with gastric cancer invading the serosa who underwent curative gastrectomy. We developed hypotonic intraperitoneal cisplatin for preventing peritoneal recurrence in experimental models. Hypotonic cisplatin had a significant tumorcidal effect in vitro and in vivo. Hypotonic intraperitoneal cisplatin was tolerable in phase I clinical study. Now, we investigated the efficacy of the treatment in a multicenter prospective randomized controlled trial. Methods: 134 pts treated with curative resection for gastric cancer invading the serosa were randomized during surgery to one of 2 treatment arms. As per protocol, eligibility was confirmed by pathology and treatment course in 108 pts as follows: A -Hypotonic intraperitoneal cisplatin (100mg/m 2 ) during surgery and systemic UFT (300mg/day) + PSK (protein-bound polysaccharide, 3g/day) (n=54) and B-Systemic UFT + PSK (n=48). Cisplatin diluted in 1,000 ml of warmed distilled water was injected to the abdominal cavity before closure of the abdomen. Drains were closed for 1 hour after injection of cisplatin. Results: Median follow up was 6.8 years. Postoperative complication rate and side effects were 21.3% and 30.8% in A-arm and 22.4% and 24.0% in B-arm. Tolerance was good in both arms. Peritoneal recurrence rate was 26.9% in A-arm and 40.0% in B-arm (chi-square p=0.16). Overall survival at 5 years was 62.0% and 31.0% in pts with or without hypotonic intraperitoneal cisplatin (log-rank p=0.03). Conclusions: Combining hypotonic intraperitoneal cisplatin and systemic oral chemotherapy improves the efficacy of oral chemotherapy after curative surgery for gastric cancer invading the serosa. No significant financial relationships to disclose.
Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China.
Authors: Tadamichi Denda, Jin Li, Ruihua Xu, Jianming Xu, Koji Ikejiri, Lin Shen, Yasushi Toh, Ken Shimada, Takeshi Kato, Hideo Baba
Journal: Journal of Clinical Oncology (2012)

598 Background: The previous phase II study of the oral S-1 plus oral Leucovorin (LV) (2 weeks’ treatment regimen followed by a 2 week rest period) for patients (pts) with untreated metastatic colorectal cancer (mCRC) have shown to be effective, but the grade 3 toxicities (diarrhea, stomatitis, and anorexia) were observed with relatively high frequency. In this phase II study, we tried to improve the administration schedule of S-1 plus LV regimens for well-tolerated toxicities and evaluated the efficacy. Methods: Pts were eligible as follows: histologically confirmed adenocarcinoma, age≥20, ECOG PS 0-1, no prior chemotherapy, at least one measurable lesion by RECIST ver1.0 criteria, adequate organ function, and written informed consent. S-1 (40-60 mg bid) and LV (25 mg bid) were orally administered for 1 week, followed by an 1 week rest period. Treatment was repeated until the onset of disease progression or unacceptable adverse events occurred. The primary endpoint was the response rate (RR), and the secondary endpoints were efficacy and safety. Results: From October 2008 to June 2009, 73 pts were enrolled in Japan and China. Of the eligible 71 pts, median age was 60 (range 27-84), Male/Female was 38/33, PS:0/1 was 39/32, and Japan/China was 32/39. RR as primary endpoint was 53.5% (95% CI, 41.3-65.5), and Disease Control Rate was 83.1%. With a median follow-up period of 26.4 months, the median Progression Free Survival was 6.5 months. Median Overall Survival was 24.3 months with the survival rate of 77.5 % at 1 year and 53.2 % at 2 years. The incidences of grade 3 adverse drug reactions were diarrhea 8.3 %, stomatitis 8.3%, anorexia 2.8%, neutropenia 9.7%, and there was no treatment-related death. Conclusions: The newly improved 1 week S-1 plus LV treatment regimen showed good efficacy and better tolerability than the 2 weeks’ treatment regimen. This therapy showed promising activity in pts with untreated mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs. This trial was supported by Taiho Pharmaceutical CO., LTD. ClinicalTrials.gov Identifier: NCT00891332 .
Phase II study: Docetaxel-cisplatin and pro drug tegafur (TPF) as neoadjuvant treatment in advanced patients with head and neck cancer (HNC): Results and correlation between tandem magnesium/creatinine and toxicity.
Authors: Manuel Santos Ortega, Gaspar Esquerdo, Jose Manuel Cervera Grau, Enrique Barrajon, Silvia Rodriguez Villalva, Marina De Piaggio, Rafael Peiro, Rita De Sanctis, Macarena Paz Espinoza Venegas
Journal: Journal of Clinical Oncology (2012)

e16025 Background: Due to hospital control difficulties of patients with HNC, a phase II with oral fluoropyrimidines was conducted. Oral administration of 5-FU itself is not feasible owing to the high activity of dihydropyridine dehydrogenase (DPD) in the gut wall. To bypass this problem, oral fluoropyrimidine derivatives were developed in the form of 5-FU prodrugs. This phase II Trial focuses on the oral 5-FU prodrug tegafur to allow similar responses and toxicities. On the other hand a secondary objective was to correlate the effect of CDDP that induces renal injury through multiple pathways. For that reason, the correlation between Mg/Cr and Toxicity was studied. Methods: From 2006 to 2011 seventeen patients with locally advanced head and neck carcinomas were treated in our institution. A phase II clinical trial was conducted as neoadjuvant treatment [docetaxel 75 m2 d-1, cisplatin 75 mgm 2 d-1, and tegafur 800 mg twice daily for 14 days, administered every 21 days with GCSF support]. If tumor response, patients received radiotherapy (RT) 70 Gy concomitant with weekly cisplatin 25mg/m2. If no response, palliative surgery or RT or/second line of chemotherapy was administered.) Results: Sixteen were male, one female, three died (2 sepsis secondary to neutropenia grade IV/ 1 secondary to direct tumor complication after 1st course of chemotherapy). Only 14 patients were evaluable for response [mean age was 54,24]. Toxicity grade &gt;2 was present in a range [13,33-21,43%]. Partial responses (PR) were present in 9 patients (52,94%), complete response or no evidence of disease in 3 (17,63%). After RT witth weekly cisplatin the diseas control was 70,57%. An association trend was detected between hypomagnesaemia and a greater toxicity. Conclusions: The implementation of an oral chemotherapy regimen has been feasible and effective with similar results to other studies. The idiosyncrasy of patients with HNC have kept their prized autonomy and independence. A new study is in progress to assess more accurately magnesium levels as predictors of severe toxicities when platinum is used.
Molecular expression profiling and pathway analysis in human renal cell carcinoma.
Authors: Vanessa Medina Villaamil, Urbano Anido, Guadalupe Aparicio Gallego, Maria Quindós Varela, Isabel Santamarina Cainzos, Manuel Valladares Ayerbes, Luis M. Antón Aparicio
Journal: Journal of Clinical Oncology (2012)

e15079 Background: Many studies have demonstrated genetic and environmental factors lead to renal cell carcinoma (RCC) occurring during a protracted period of tumorigenesis. It seemed suitable identify and characterize potential molecular markers appearing during of tumorigenesis which might provide rapid and effective possibilities for early detection of RCC. Methods: We assessed using quantitative real-time PCR (qPCR) the profile of 32 markers involved in the cascade of events leading to the formation and progression of RCC: invasiveness, angiogenesis and antiapoptotic mechanisms. RNA of quality was obtained in 90% of samples (N=80, 64/80 clear RCC, 8/80 papillary RCC and 8/80 chromophobe RCC) to carry out the study of gene expression. Nonparametric tests (Pearson's correlation coefficient test and Spearman's rho test, Kruskal — Wallis and Mann — Whitney) and Bonferroni post-hoc test were applied for statistical data analysis. Additionally, a knowledgebase of biological pathways, Reactome, was used to superimpose our quantitative expression data. Results: Statistical analysis comparing medians and means showed the following candidates as the best gene predictors related to different pathological variables (histological type, number of involved nodes, renal pelvis invasion, lymphatic vessels invasion and rupture of the renal capsule): Hif1-α (p&lt;.001), Hif1-β (p=.035), DLL1 (p=0.012), DLL3 (p&lt;.001), c-Kit (p=.002), PDGFR-β (p=.002), PDGFR-α (p=0.026), Bax-β (p=.005), Survivin (p=.028), Notch1 (p=.006), Notch2 (p=.007), Notch3 (p=.016), Notch4 (p=.005), EGFR (p=.029), Glut3 (p=.026), Glut5 (p=.036) and FH (p=.018). Analysis of these genes expression profiles in Reactome tool revealed those cellular pathways over-represented in our RCC cohort, among others, Extrinsic Pathway for Apoptosis and Double-Strand Break Repair (100 and 95% matching in our data, respectively). Conclusions: Our study highlights the reasons to deepen in the knowledge of pathways components and their associations with the underlying pathology characteristics in order to understand the molecular pathology of a tumor and how that influences its biologic behavior. More detailed studies of these pathways are in progress.
Covid-19 fatality is likely overestimated
Authors: Joshua D Niforatos, Edward R Melnick, Jeremy S Faust
Journal: BMJ (2020)

The final case fatality rate (CFR) from SARS-CoV-2, the virus that causes covid-19, will likely be lower than those initially reported.1 Previous reviews of H1N1 and SARS show the systematic inflation of early mortality estimates.23 Early estimates of H1N1’s mortality were susceptible to uncertainty about asymptomatic and subclinical infections, heterogeneity in approaches to diagnostic testing, and biases in confounding, selection, detection, reporting, …
THE SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR DAPAGLIFLOZIN EXERTS CARDIOPROTECTIVE EFFECTS AGAINST DOXORUBICIN AND TRASTUZUMAB TOXICITY THROUGH TLR4/MYD88/NF-KB SIGNALING AND NLRP3 INFLAMMASOME PATHWAY
Authors: Nicola Maurea, Vincenzo Quagliariello, Rosario Vincenzo Iaffaioli, Michelino De Laurentiis, Gerardo Botti
Journal: Journal of the American College of Cardiology (2020)
NanoVar: accurate characterization of patients’ genomic structural variants using low-depth nanopore sequencing
Authors: Cheng Yong Tham, Roberto Tirado-Magallanes, Yufen Goh, Melissa J. Fullwood, Bryan T.H. Koh, Wilson Wang, Chin Hin Ng, Wee Joo Chng, Alexandre Thiery, Daniel G. Tenen, Touati Benoukraf
Journal: Genome biology (2020)

Abstract The recent advent of third-generation sequencing technologies brings promise for better characterization of genomic structural variants by virtue of having longer reads. However, long-read applications are still constrained by their high sequencing error rates and low sequencing throughput. Here, we present NanoVar, an optimized structural variant caller utilizing low-depth (8X) whole-genome sequencing data generated by Oxford Nanopore Technologies. NanoVar exhibits higher structural variant calling accuracy when benchmarked against current tools using low-depth simulated datasets. In patient samples, we successfully validate structural variants characterized by NanoVar and uncover normal alternative sequences or alleles which are present in healthy individuals.
STANDALONE THORACOSCOPIC EPICARDIAL LEFT ATRIAL APPENDAGE EXCLUSION FOR THROMBOEMBOLISM PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
Authors: Richard G. Cartledge, Gary Gottlieb, Anthony Cioci, Grzegorz Suwalski, Anna Witkowska, Gilbert Chidiac, Burak Ilsin, Barry Merrill, Piotr Suwalski
Journal: Journal of the American College of Cardiology (2020)
GRAFT PATENCY AND PROGRESSION OF CORONARY ARTERY DISEASE AFTER CABG ASSESSED BY ANGIOGRAPHY-DERIVED FRACTIONAL FLOW RESERVE
Authors: Sakura Nagumo, Carlo Gigante, Takuya Mizukami, Jeroen Sonck, Alessandra Tanzilli, Jozef Bartunek, Marc Vanderheyden, Eric Wyffels, Emanuele Barbato, Bernard De Bruyne, Daniele Andreini, Carlos Collet
Journal: Journal of the American College of Cardiology (2020)
ACUTE CHANGES IN LEFT VENTRICULAR CARDIAC MECHANICS AFTER MITRACLIP TREATMENT OF MITRAL REGURGITATION
Authors: Stamatios Lerakis, Richard Ro, Wenli Zhao, Karthik Seetharam, Parasuram Krishnamoorthy, Nagendra Boopathy Senguttuvan, Gilbert Tang, Gregg Stone, Samin K. Sharma, Annapoorna Subhash Kini
Journal: Journal of the American College of Cardiology (2020)
SPOT-Disorder2: Improved Protein Intrinsic Disorder Prediction by Ensembled Deep Learning
Authors: Jack Hanson, Kuldip K. Paliwal, Thomas Litfin, Yaoqi Zhou
Journal: Genomics Proteomics & Bioinformatics (2019)

Abstract Intrinsically disordered or unstructured proteins (or regions in proteins) have been found to be important in a wide range of biological functions and implicated in many diseases. Due to the high cost and low efficiency of experimental determination of intrinsic disorder and the exponential increase of unannotated protein sequences, developing complementary computational prediction methods has been an active area of research for several decades. Here, we employed an ensemble of deep Squeeze-and-Excitation residual inception and long short-term memory (LSTM) networks for predicting protein intrinsic disorder with input from evolutionary information and predicted one-dimensional structural properties. The method, called SPOT-Disorder2, offers substantial and consistent improvement not only over our previous technique based on LSTM networks alone, but also over other state-of-the-art techniques in three independent tests with different ratios of disordered to ordered amino acid residues, and for sequences with either rich or limited evolutionary information. More importantly, semi-disordered regions predicted in SPOT-Disorder2 are more accurate in identifying molecular recognition features (MoRFs) than methods directly designed for MoRFs prediction. SPOT-Disorder2 is available as a web server and as a standalone program at https://sparks-lab.org/server/spot-disorder2/.
Association between smoking and tumor grade in colorectal cancer: A retrospective analysis from a single institution.
Authors: Raymond Elsoueidi, Sabrina Tom, Eyob Adane, Mark Dignan
Journal: Journal of Clinical Oncology (2013)

e14673 Background: Colorectal cancer is the third most common cancer worldwide. Smoking has been increasingly reported as a risk factor. Poorly differentiated adenocarcinoma in colorectal cancer has been reported to have a worse outcome. Poorly and moderately differentiated adenocarcinomas in Non Small Cell Lung cancer were more strongly correlated with smoking than well differentiated adenocarcinoma. This study was designed to evaluate the association between cigarette smoking and tumor grade in colorectal cancer. Methods: The medical records of patients diagnosed with colorectal cancer between 2001 and 2011 at the Appalachian Regional Healthcare in Hazard, KY were retrospectively reviewed. Age, gender, pathology and smoking history were obtained. The association between smoking and tumor grade was evaluated by the χ 2 test. Results: Three hundred seventeen patients were diagnosed with colorectal cancer between 2001 and 2011. The percentage of male and female patients was 53.3% and 46.7%, respectively. Among these patients, 49.5% (n=157) were smokers and 38.8% were nonsmokers (n=138), while for 11.7% (n=35) of patients smoking history was unknown. In smokers, 17.1% had high grade adenocarcinoma (poorly differentiated) and 82.9% had low grade adenocarcinoma (moderately differentiated + well differentiated) whereas in non-smokers, 13.8% had high grade adenocarcinoma and 86.2% had low grade adenocarcinoma. Although the percentage of high grade adenocarcinoma was higher among smokers this was not statistically significantly (p=0.55). Moreover, tumor grade was not significantly associated with age and gender. Conclusions: Based on these results, there was no association between degree of differentiation of tumor in colorectal cancer and smoking history, age and gender. Although to be noted that the pathologic grading may vary from one pathologist to another.
The cost implications of prostate cancer screening in the Medicare population.
Authors: Xiaomei Ma, Rong Wang, Jessica B. Long, Joseph S. Ross, Pamela R. Soulos, James B. Yu, Danil V. Makarov, Heather Taffet Gold, Cary Philip Gross
Journal: Journal of Clinical Oncology (2013)

6549 Background: Recent debate about prostate specific antigen (PSA)-based testing for prostate cancer screening among older men has rarely considered the cost associated with screening. Methods: We assembled a population-based cohort of male Medicare beneficiaries aged 66-99 years who had never been diagnosed with prostate cancer at the end of 2005 (n = 84,699) and followed them for two years to assess the cost of PSA screening and downstream procedures (biopsy, pathology, and hospitalization due to biopsy complications) at both the national and the hospital referral region (HRR) level. The relation of screening cost to stage of prostate cancer at diagnosis at the HRR level was analyzed using multivariate Poisson models. We also evaluated the initial treatment cost of Medicare fee for service beneficiaries diagnosed with prostate cancer during 2006-2007 (n = 31,653). Results: Approximately 42.8% of the 84,699 men received PSA screening tests during the two-year study period, with 2.4% undergoing biopsy. The annual expenditures by the national fee for service Medicare program were $454 million for screening and $1.79 billion for initial treatment (in 2009 US dollars). The mean annual screening cost at the regional (HRR) level ranged from $16 to $65 per beneficiary. Downstream biopsy-related procedures (biopsy, pathology, and hospitalization due to biopsy complications) accounted for 73% of the overall screening costs and varied significantly across regions. Compared with men residing in HRRs that were in the lowest quartile for screening expenditures, men living in the highest HRR quartile were significantly more likely to be diagnosed with prostate cancer of any stage [incidence rate ratio (IRR) = 1.23, 95% confidence interval (CI): 1.07-1.42] and localized cancer (IRR = 1.31, 95% CI: 1.13-1.53). Conclusions: Medicare prostate cancer screening-related expenditures are substantial, vary considerably across regions, and are positively associated with rates of cancer diagnosis.